Loading
A phase 1/2 trial of INO-5401, Cemiplimab and Temozolomide in glioma & glioblastoma, run by Inovio Pharmaceuticals, active and no longer recruiting.
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) is a phase 1/2 interventional study registered as NCT03491683 by Inovio Pharmaceuticals, with 52 participants enrolled, started 2018-05-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: INO-5401, INO-9012, Cemiplimab, Radiation Therapy and Temozolomide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Temozolomide, Glioma & glioblastoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Cemiplimab, Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/